IRCT20170509033894N3已完成3 期
Comprasion of additive effect of solifenacin with tolterodine to desmopressin in treatment of children with primary nocturnal enuresis
Vice Chancellor for Research and Technology of Ahvaz Jundishapur University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5 years 至 15 years（—）
- 性别
- All
入选标准
- •children with primary nucturnal enurises
排除标准
- •patients with neurogenic bladder
- •CNS disorders
- •urine-concentrating defects
研究者
相似试验
招募中
2 期
Comparison of the efficacy of solifenacin and duloxetine in the treatment of overactive bladder diseaseIRCT20191010045047N1Kerman University of Medical Sciences60
已完成
4 期
Comparative evaluation of solifenacin and darifenacin for prevention of catheter related bladder discomfortCTRI/2014/08/004934Apollo Hospitals Bilaspur90
已完成
4 期
Efficacy of Solifenacin and trospium chloride on neurogenic bladderCondition 1: stroke. Condition 2: neurogenic bladder.Cerebrovascular disease, unspecifiedNeuromuscular dysfunction of bladder, unspecifiedI67.9N31.9IRCT20160606028304N2Tabriz University of Medical Sciences201
进行中（未招募）
1 期
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINKOveractive bladderMedDRA version: 12.0Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2008-005215-17-HUAstellas Pharma Europe Limited639
进行中（未招募）
不适用
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINKOveractive bladderMedDRA version: 12.0Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2008-005215-17-BGAstellas Pharma Europe Limited639